TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX) was the target of some unusual options trading on Wednesday. Investors bought 9,165 call options on the stock. This represents an increase of 230% compared to the average volume of 2,781 call options.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on TGTX shares. Zacks Research upgraded shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st. Wall Street Zen cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of TG Therapeutics in a research report on Wednesday, May 27th. Finally, Weiss Ratings raised TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $52.50.

TG Therapeutics Trading Up 8.1%

Shares of TGTX traded up $3.53 during trading hours on Wednesday, reaching $46.90. 3,546,382 shares of the company traded hands, compared to its average volume of 2,073,928. The stock’s fifty day moving average price is $37.46 and its 200 day moving average price is $32.77. The company has a current ratio of 5.81, a quick ratio of 5.12 and a debt-to-equity ratio of 1.28. The firm has a market cap of $7.18 billion, a price-to-earnings ratio of 16.43 and a beta of 1.68. TG Therapeutics has a 12-month low of $25.28 and a 12-month high of $49.31.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.11). The firm had revenue of $204.92 million for the quarter, compared to analysts’ expectations of $200.33 million. TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The company’s revenue for the quarter was up 69.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.03 earnings per share. Sell-side analysts forecast that TG Therapeutics will post 1.51 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Congress Asset Management Co. acquired a new stake in shares of TG Therapeutics during the fourth quarter worth about $57,307,000. Man Group plc lifted its stake in TG Therapeutics by 621.5% during the 3rd quarter. Man Group plc now owns 1,008,462 shares of the biopharmaceutical company’s stock valued at $36,431,000 after acquiring an additional 868,697 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of TG Therapeutics by 856.6% in the 4th quarter. BNP Paribas Financial Markets now owns 683,653 shares of the biopharmaceutical company’s stock valued at $20,380,000 after acquiring an additional 612,189 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of TG Therapeutics by 129.5% during the first quarter. Dimensional Fund Advisors LP now owns 1,084,855 shares of the biopharmaceutical company’s stock worth $36,029,000 after purchasing an additional 612,068 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in TG Therapeutics by 71.7% during the first quarter. Bank of America Corp DE now owns 1,461,302 shares of the biopharmaceutical company’s stock valued at $48,544,000 after purchasing an additional 610,195 shares during the period. 58.58% of the stock is owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small?molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.